AGILON HEALTH INC (AGL) Stock Fundamental Analysis

NYSE:AGL • US00857U1079

0.3735 USD
+0.01 (+2.78%)
Last: Feb 13, 2026, 09:37 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

AGL gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 102 industry peers in the Health Care Providers & Services industry. The financial health of AGL is average, but there are quite some concerns on its profitability. AGL is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year AGL has reported negative net income.
  • AGL had a negative operating cash flow in the past year.
  • AGL had negative earnings in each of the past 5 years.
  • In the past 5 years AGL always reported negative operating cash flow.
AGL Yearly Net Income VS EBIT VS OCF VS FCFAGL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -100M -200M -300M -400M

1.2 Ratios

  • With a Return On Assets value of -19.32%, AGL is not doing good in the industry: 79.41% of the companies in the same industry are doing better.
  • AGL's Return On Equity of -100.78% is on the low side compared to the rest of the industry. AGL is outperformed by 74.51% of its industry peers.
Industry RankSector Rank
ROA -19.32%
ROE -100.78%
ROIC N/A
ROA(3y)-12.12%
ROA(5y)-15.09%
ROE(3y)-35.05%
ROE(5y)-76.94%
ROIC(3y)N/A
ROIC(5y)N/A
AGL Yearly ROA, ROE, ROICAGL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

  • Looking at the Gross Margin, with a value of 0.51%, AGL is doing worse than 80.39% of the companies in the same industry.
  • AGL's Gross Margin has declined in the last couple of years.
  • AGL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 0.51%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-29.21%
GM growth 5Y-16.16%
AGL Yearly Profit, Operating, Gross MarginsAGL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 10 -10 -20 -30

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • AGL does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, AGL has more shares outstanding
  • The number of shares outstanding for AGL has been increased compared to 5 years ago.
  • AGL has a better debt/assets ratio than last year.
AGL Yearly Shares OutstandingAGL Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M
AGL Yearly Total Debt VS Total AssetsAGL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

  • Based on the Altman-Z score of 1.49, we must say that AGL is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of 1.49, AGL is doing worse than 60.78% of the companies in the same industry.
  • There is no outstanding debt for AGL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.49
ROIC/WACCN/A
WACC9.73%
AGL Yearly LT Debt VS Equity VS FCFAGL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M 1B

2.3 Liquidity

  • AGL has a Current Ratio of 1.08. This is a normal value and indicates that AGL is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Current ratio value of 1.08, AGL is not doing good in the industry: 65.69% of the companies in the same industry are doing better.
  • A Quick Ratio of 1.08 indicates that AGL should not have too much problems paying its short term obligations.
  • AGL's Quick ratio of 1.08 is in line compared to the rest of the industry. AGL outperforms 40.20% of its industry peers.
Industry RankSector Rank
Current Ratio 1.08
Quick Ratio 1.08
AGL Yearly Current Assets VS Current LiabilitesAGL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 500M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • AGL shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 3.85%.
  • The Revenue has grown by 9.94% in the past year. This is quite good.
  • Measured over the past years, AGL shows a very strong growth in Revenue. The Revenue has been growing by 50.14% on average per year.
EPS 1Y (TTM)3.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%6.9%
Revenue 1Y (TTM)9.94%
Revenue growth 3Y48.96%
Revenue growth 5Y50.14%
Sales Q2Q%-1.08%

3.2 Future

  • AGL is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.30% yearly.
  • Based on estimates for the next years, AGL will show a small growth in Revenue. The Revenue will grow by 7.42% on average per year.
EPS Next Y-25.81%
EPS Next 2Y15.14%
EPS Next 3Y16.3%
EPS Next 5Y15.3%
Revenue Next Year-3.81%
Revenue Next 2Y-0.76%
Revenue Next 3Y2.8%
Revenue Next 5Y7.42%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
AGL Yearly Revenue VS EstimatesAGL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2B 4B 6B 8B
AGL Yearly EPS VS EstimatesAGL Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for AGL. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AGL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AGL Price Earnings VS Forward Price EarningsAGL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AGL Per share dataAGL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

  • AGL's earnings are expected to grow with 16.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.14%
EPS Next 3Y16.3%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • AGL does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AGILON HEALTH INC

NYSE:AGL (2/13/2026, 9:37:49 AM)

0.3735

+0.01 (+2.78%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-04
Earnings (Next)02-25
Inst Owners68.58%
Inst Owner Change-0.48%
Ins Owners1.92%
Ins Owner Change5.49%
Market Cap154.85M
Revenue(TTM)5.89B
Net Income(TTM)-308.46M
Analysts55
Price Target1.01 (170.41%)
Short Float %6.67%
Short Ratio2.66
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-91.76%
Min EPS beat(2)-114.66%
Max EPS beat(2)-68.86%
EPS beat(4)1
Avg EPS beat(4)56.59%
Min EPS beat(4)-114.66%
Max EPS beat(4)422.51%
EPS beat(8)3
Avg EPS beat(8)6.64%
EPS beat(12)4
Avg EPS beat(12)-1.81%
EPS beat(16)4
Avg EPS beat(16)-22.58%
Revenue beat(2)0
Avg Revenue beat(2)-3.16%
Min Revenue beat(2)-6.13%
Max Revenue beat(2)-0.19%
Revenue beat(4)1
Avg Revenue beat(4)-1.49%
Min Revenue beat(4)-6.13%
Max Revenue beat(4)0.91%
Revenue beat(8)2
Avg Revenue beat(8)-1.54%
Revenue beat(12)6
Avg Revenue beat(12)0.25%
Revenue beat(16)10
Avg Revenue beat(16)0.78%
PT rev (1m)2.16%
PT rev (3m)-29.59%
EPS NQ rev (1m)2.95%
EPS NQ rev (3m)-16.17%
EPS NY rev (1m)0.21%
EPS NY rev (3m)-28.74%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.47%
Revenue NY rev (1m)0.02%
Revenue NY rev (3m)0.15%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.03
P/FCF N/A
P/OCF N/A
P/B 0.51
P/tB 0.75
EV/EBITDA N/A
EPS(TTM)-0.75
EYN/A
EPS(NY)-0.42
Fwd EYN/A
FCF(TTM)-0.28
FCFYN/A
OCF(TTM)-0.17
OCFYN/A
SpS14.2
BVpS0.74
TBVpS0.5
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -19.32%
ROE -100.78%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 0.51%
FCFM N/A
ROA(3y)-12.12%
ROA(5y)-15.09%
ROE(3y)-35.05%
ROE(5y)-76.94%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-29.21%
GM growth 5Y-16.16%
F-Score4
Asset Turnover3.69
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 164.16%
Cap/Sales 0.77%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.08
Quick Ratio 1.08
Altman-Z 1.49
F-Score4
WACC9.73%
ROIC/WACCN/A
Cap/Depr(3y)186.26%
Cap/Depr(5y)133.4%
Cap/Sales(3y)0.87%
Cap/Sales(5y)0.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%6.9%
EPS Next Y-25.81%
EPS Next 2Y15.14%
EPS Next 3Y16.3%
EPS Next 5Y15.3%
Revenue 1Y (TTM)9.94%
Revenue growth 3Y48.96%
Revenue growth 5Y50.14%
Sales Q2Q%-1.08%
Revenue Next Year-3.81%
Revenue Next 2Y-0.76%
Revenue Next 3Y2.8%
Revenue Next 5Y7.42%
EBIT growth 1Y-8.74%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year7.32%
EBIT Next 3Y23.2%
EBIT Next 5Y19.5%
FCF growth 1Y32.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y52.25%
OCF growth 3YN/A
OCF growth 5YN/A

AGILON HEALTH INC / AGL FAQ

What is the ChartMill fundamental rating of AGILON HEALTH INC (AGL) stock?

ChartMill assigns a fundamental rating of 2 / 10 to AGL.


Can you provide the valuation status for AGILON HEALTH INC?

ChartMill assigns a valuation rating of 0 / 10 to AGILON HEALTH INC (AGL). This can be considered as Overvalued.


Can you provide the profitability details for AGILON HEALTH INC?

AGILON HEALTH INC (AGL) has a profitability rating of 0 / 10.


What is the earnings growth outlook for AGILON HEALTH INC?

The Earnings per Share (EPS) of AGILON HEALTH INC (AGL) is expected to decline by -25.81% in the next year.